SCHEMBL4026464

SCHEMBL4026464

CCOC(=O)C1C2CCC(C2)N1S(=O)(=O)c1ccc(Oc2ccncc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.45
PKM P14618 1/20 0.45
ALDH1A1 P00352 6/20 0.43
LMNA P02545 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MMP1 P03956 2/20 0.41
MMP3 P08254 2/20 0.41
MMP13 P45452 2/20 0.41
MMP7 P09237 2/20 0.41
HTT P42858 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 2/20 0.40
HSD11B1 P28845 1/20 0.40
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP8 P22894 1/20 0.39
MMP14 P50281 1/20 0.39
ADAM17 P78536 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4032569 0.86 ALDH1A1 (0.56) KMT2APKMALDH1A1LMNAL3MBTL1
SCHEMBL4028052 0.82 MMP1 (0.52) ALDH1A1MMP1MMP3MMP13MMP7
SCHEMBL14535952 0.78 ALDH1A1 (0.60) KMT2APKMALDH1A1LMNAL3MBTL1
SCHEMBL4034942 0.77 ALDH1A1 (0.55) KMT2APKMALDH1A1LMNAL3MBTL1
SCHEMBL1770227 0.74 KMT2A (0.55) KMT2APKMALDH1A1LMNAHTT
SCHEMBL1770228 0.74 KMT2A (0.55) KMT2APKMALDH1A1LMNAHTT
SCHEMBL1770230 0.74 KMT2A (0.55) KMT2APKMALDH1A1LMNAHTT
SCHEMBL9082047 0.72 ALDH1A1 (0.37) KMT2APKMALDH1A1LMNAL3MBTL1
SCHEMBL6480554 0.72 ALDH1A1 (0.59) KMT2APKMALDH1A1LMNAL3MBTL1
SCHEMBL4031087 0.72 ALDH1A1 (0.59) KMT2APKMALDH1A1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1452527-B1 AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION SHISEIDO CO LTD (JP) 2009-03-04 EP disclosed
US-7176217-B2 Azabicyclo compound matrix metalloprotease inhibitor and skin preparation SHISEIDO CO., LTD. (JP) 2007-02-13 US disclosed
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation SHISEIDO CO., LTD. (JP) 2005-01-13 US disclosed
EP-1452527-A1 AZABICYCLO COMPOUND, MATRIX METALLOPROTEASE INHIBITOR, AND SKIN PREPARATION Shiseido Co., Ltd. (JP) 2004-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009808-A1 Azabicyclo compound matrix metalloprotease inibitor and skin preparation MMP1, MMP16, MMP9 KMT2A 927/4885PKM 4744/4885ALDH1A1 1160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.